GRTS_2021_logoupdate_color.jpg
Gritstone bio Announces Positive Preliminary Progression-free Survival and Long-term Circulating Tumor DNA (ctDNA) Data from Phase 2 Portion of Ongoing Phase 2/3 Study of its Personalized Cancer Vaccine, GRANITE, in Front-line Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)
01 avr. 2024 16h01 HE | Gritstone bio
-- Early progression-free survival (PFS) trends favor GRANITE recipients with hazard ratios of 0.82 in the overall population ([95% CI, 0.34-1.67]; 62% censored) and 0.52 (48% relative risk reduction...
Research Nester Logo.jpg
Blood Group Typing Market revenue to hit USD 2 Billion by 2033, says Research Nester
05 févr. 2024 06h00 HE | Research Nester
New York , Feb. 05, 2024 (GLOBE NEWSWIRE) -- The global blood group typing market size is slated to expand at 7% CAGR between 2023 and 2033. The market is poised to garner a revenue of USD 2 billion...
Dyadic Logo Current.jpg
Dyadic Provides Phase 1 Clinical Trial Update for its Recombinant Protein RBD Vaccine Candidate
24 juil. 2023 08h30 HE | Dyadic International, Inc.
Dosing of patients completed at the end of FebruaryData Safety Monitoring Board conducted analysis of Day 29 data No major vaccine-related safety concerns for either of the two dose levelsNo Serious...
Vaccitech Logo.png
Vaccitech Doses First Patient in PCA001, a Prostate Cancer Phase 1/2 Clinical Trial of VTP-850 Immunotherapeutic Candidate in Men with Rising PSA after Definitive Local Therapy
12 juin 2023 07h30 HE | Vaccitech plc
OXFORD, United Kingdom, June 12, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) (the Company, we or us), a clinical-stage biopharmaceutical company engaged in the discovery and development of...
Dyadic Logo Current.jpg
Dyadic to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023
26 avr. 2023 16h30 HE | Dyadic International, Inc.
JUPITER, Fla., April 26, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...
Dyadic Logo Current.jpg
Dyadic to Present at Roth Investor Conference and Upcoming Industry Events
01 mars 2023 08h30 HE | Dyadic International, Inc.
JUPITER, Fla., March 01, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
TIP_link_300x300.jpg
Immunodiagnostics Market to Gain $29.52 Bn by 2028 with Booming CAGR Value of 7.4% | The Insight Partners
30 nov. 2022 07h31 HE | The Insight Partners
New York, Nov. 30, 2022 (GLOBE NEWSWIRE) -- According to The Insight Partners latest study on "Immunodiagnostics Market Size, Share, Growth, Trends and Forecast to 2028 – COVID-19 Impact and Global...
Dyadic Logo Current.jpg
Dyadic Receives Regulatory Approval to Initiate Phase 1 Clinical Trial to Demonstrate Clinical Safety and Efficacy in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
27 oct. 2022 09h04 HE | Dyadic International, Inc.
JUPITER, Fla., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...
EVAXION_BLACK_RGB.jpg
Evaxion welcomes Per Norlén as new CEO.
05 oct. 2022 08h32 HE | Evaxion Biotech
COPENHAGEN, Denmark, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of...
Beroni Logo @ Dec 2019.png
Beroni Group Announced the Latest Clinical Study of its SARS-CoV-2 Antigen Test Kit (Colloidal Gold Method)
31 août 2021 08h30 HE | Beroni Group Limited
NEW YORK and SYDNEY, Australia, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni”), an Australia-based biopharmaceutical enterprise, announced the latest clinical...